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Abstract
Highly pathogenic H5N1 influenza infections are associated with enhanced inflammatory and cytokine responses, severe
lung damage, and an overall dysregulation of innate immunity. C3, a member of the complement system of serum proteins,
is a major component of the innate immune and inflammatory responses. However, the role of this protein in the
pathogenesis of H5N1 infection is unknown. Here we demonstrate that H5N1 influenza virus infected mice had increased
levels of C5a and C3 activation byproducts as compared to mice infected with either seasonal or pandemic 2009 H1N1
influenza viruses. We hypothesized that the increased complement was associated with the enhanced disease associated
with the H5N1 infection. However, studies in knockout mice demonstrated that C3 was required for protection from
influenza infection, proper viral clearance, and associated with changes in cellular infiltration. These studies suggest that
although the levels of complement activation may differ depending on the influenza virus subtype, complement is an
important host defense mechanism.
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Introduction
Since emerging in 1997, highly pathogenic avian influenza
(HPAI) H5N1 viruses have been associated with over 500 human
infections with an unprecedented fatality rate exceeding 60%. The
significant virulence of these viruses, their continual evolution in
birds, and the co-circulation of the pandemic H1N1 virus lead to
concerns that the H5N1 viruses pose pandemic threats.
The severe disease associated with HPAI H5N1 infections in
humans and animals could result from several factors including
dissemination of the virus beyond the respiratory tract, higher and
prolonged viral replication leading to increased viral cytolytic
damage, differences in the host response induced by the H5N1
viruses, or a combination of all these factors. Although host
responses are clearly complex, the clinical data and animal models
suggest that the innate immune responses differ in H5N1 infected
individuals (reviewed in [1,2]). As compared to seasonal influenza
infection H5N1 infected patients have elevated serum levels of
several chemokines and cytokines [3,4,5]. Similar results were
observed in animal models where H5N1 infection is associated
with elevated cytokine and chemokine levels [2,6,7,8,9], enhanced
recruitment of macrophages and neutrophils into the lungs leading
to acute lung inflammation [10], and premature apoptosis of
dendritic cells [11]. This aberrant host response is reminiscent of
1918 influenza virus infected animals [10,12].
A major component of the innate immune response that has not
been evaluated during HPAI H5N1 infections is complement. The
complement system is comprised of more than 30 proteins
responsible for recognizing and eliminating pathogens while
stimulating early and late cellular functions (reviewed in [13]).
Three biochemical pathways activate the complement system: the
classical complement pathway, the alternative complement
pathway, and the mannose-binding lectin pathway [14]. The
hydrolysable C3 protein is the converging point for all three
complement activation pathways, making it the central player in
the complement cascade [15]. Upon activation, C3 is cleaved into
C3a and C3 convertase, which supports the further cleavage of C5
into C5a. C3a and C5a function similar to chemokines promoting
localized attraction and activation of immune cells including
neutrophils, which serve an important role in early and late
defense against pathogens including influenza virus [16,17,18,19].
A recent study by Boon et al demonstrated a protective role for
complement C5 in H5N1 influenza pathogenesis [20]. Thus, the
goal of these studies was to fill our gap in knowledge by
determining if mice infected with H5N1 influenza virus differed
in complement C3 activation as compared to a seasonal or the
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17377pandemic 2009 H1N1 influenza virus and if C3 was required for
protection from HPAI H5N1 influenza infection.
Results
H5N1 influenza virus increases C3 and C5a lung levels as
compared to seasonal or pandemic influenza strains
To quantitate C3 and C5a protein levels during influenza
infection, C57BL/6 mice were lightly anesthetized and intrana-
sally inoculated with PBS (uninfected control), seasonal H1N1 A/
Puerto Rico/8/1934 (PR/8), pandemic 2009 H1N1 A/Califor-
nia/7/2009 (CA/09), or HPAI H5N1 A/Vietnam/1194/04 (VN/
1194) and bronchioalveolar lavage (BAL) collected on days 1, 3,
and 6 post-infection (pi). Using a mouse-specific C3 sandwich
ELISA we found that within 3 days post-infection (dpi) C3 levels
were .3-fold higher in the H5N1 VN/1194 virus infected mice as
compared to controls and continued to increase to .4-fold by
6 dpi (Fig. 1A). This is in contrast to mice infected with seasonal
(PR/8) or pandemic (CA/09) viruses where C3 levels never
increased above control. A similar trend was observed for C5a.
H5N1 VN/1194 infected mice had increased C5a levels within
3 dpi (,2-fold) increasing to .4-fold by 6 dpi as compared to
uninfected controls (Fig. 1B). There was no significant increase in
PR/8 and CA/09 virus infected mice.
To monitor C3 processing in the BAL, immunoblotting was
performed under reducing conditions with a polyclonal anti-C3
antibody and protein loading determined by anti-actin antibody
([21]; Fig. 1C and Fig. S1). To quantitate differences, densitometry
was performed as compared to actin and results expressed as the
fold change over uninfected controls (Fig. 1D). The anti-C3
antibody detected 2 major proteins at ,65 and ,43 kDa, which
are likely bC3 and iC3b respectively. Mouse/rat C3 byproducts
run at slightly different sizes than human [22,23]. Similar to the
C3 ELISA data, H5N1 VN/1194 infected animals had increased
levels of both bC3 and iC3b in BAL at 3 and 6 dpi (Fig. 1C and
D). Mice infected with seasonal PR/8 virus had levels at or below
control uninfected throughout the course of infection. Comparable
results were observed with the pandemic CA/09 infected mice
except for a dramatic increase in iC3b levels at 3 dpi only. The
reason for this is unclear and no increase was seen in the ELISA.
Parallel trends were seen in BALB/c mice and mice infected with
other strains of HPAI H5N1 virus suggesting that these results are
not mouse or H5N1 VN/1194 strain specific (data not shown). In
summation, these results suggest that H5N1 virus elicits higher
levels of C5a and C3 in the lungs of infected mice.
Increased morbidity and exacerbated inflammation in
the lungs of C3
2/2 infected mice
Increased complement has been associated with enhanced
inflammation and tissue destruction [24]. Thus, we hypothesized
that the elevated complement levels in the HPAI H5N1 infected
mice could be involved in the prominent inflammatory response
associated with these infections. To evaluate this, wild-type (WT)
and C3 knockout mice (C3
2/2) mice were intranasally inoculated
with PBS (control), CA/09, or H5N1 VN/1194 virus, lungs
collected at 3 (Fig. 2) and 6 dpi (Fig. 3) and histopathology
performed. To evaluate the infiltrating cell population, tissues
were stained for macrophages and neutrophils and quantitated by
ImageScope. By 3 dpi, both the CA/09 (Fig. 2H) and VN/1194
(Fig. 2N) infected C3
2/2 mice had enhanced inflammation as
compared to WT (Fig. 2G and 2M) with the VN/1194 being more
severe. In the CA/09 infected C3
2/2 mice, this was associated
with increased numbers of macrophages (Fig. 2J) as compared to
WT (Fig. 2I). Quantitative analysis showed an increase from
,17% positive cells in WT to ,34% in C3
2/2 mice (Fig. 4A).
There was no change in neutrophil levels (Fig. 2K and L). Tissues
from uninfected control animals are shown in Fig. 2A–F.
Although inflammation was more apparent in the H5N1 VN/
1194 infected C3
2/2 mice, this was not associated with significant
differences in the numbers of macrophage or neutrophil as
compared to WT (Fig. 2O–R). Both strains of mice had minimal
numbers of macrophages and ,10% staining for neutrophils
(Fig. 4A). These numbers were significantly lower than those seen
in CA/09 infected animals; regardless of the strain.
By 6 dpi, there was increased inflammation in the C3
2/2 mice
as compared to WT; including uninfected C3
2/2 mice (Fig. 3B
versus 3A). The CA/09 infected WT mice exhibited mild
bronchiolitis and perivasculitis (Fig. 3G) comprised of both
macrophages (Fig. 3I) and neutrophils (Fig. 3K). In contrast, the
CA/09 infected C3
2/2 mice had moderate to moderately severe
bronchitis, bronchiolitis, and vasculitis, with perivasculitis, consol-
idation (Fig. 3H) and increased numbers of macrophages (Fig. 3J).
Quantitative analysis showed an increase from ,17% positive cells
in WT to ,42% in C3
2/2 mice (Fig. 4A). What was most evident
was the decrease in neutrophil numbers in the C3
2/2 mice from
,22% in WT to ,10% in C3
2/2 mice (Fig. 4A).
Although the pathologic changes were similar, the most
prominent difference between VN/1194 infected WT and C3
2/2
mice was the extent of the damage. VN/1194 infected WT mice
had increased inflammation and damage in localized areas of the
lung, primarily at the edges of the bronchi (Fig. 3M). In contrast,
infected C3
2/2 mice displayed a more diffuse, non-focal
pathology with increased interstitial involvement (Fig. 3N). This
was associated with an increase in neutrophils (Fig. 3R versus 3Q).
Neutrophillevels increased from ,25% in WT to ,40% in C3
2/2
mice (Fig. 4A). To determine if the changes in inflammation played
a role in pathogenesis, infected mice were monitored for weight loss
(Fig. 4B). By 8 dpi, the influenza infected C3
2/2 mice had lost
.25% of their day 0 weights (CA/09 p,0.009, VN/1194 p,0.05)
and had to be humanely euthanized. In contrast, the infected WT
mice never lost more than 8% of their day 0 weights (CA/09
p,0.005, VN/1194 p,0.0001).
Delayed viral clearance in C3
2/2 infected mice
Finally to better understand the mechanism of C3-mediated
protection, viral titers were measured in the lungs on days 3, 6,
and 8 pi (Fig. 5). In CA/09-infected WT mice, lung titers were
highest 3 dpi (10
6.5 TCID50/ml) and decreased to approximately
10
3.5 TCID50/ml by 8 dpi (Fig. 5). In contrast, the C3
2/2 infected
mice had significantly higher viral titers at days 6 (p,0.04) and
8p i( p,0.03) suggesting a delay in viral clearance. Similar trends
were observed in the VN/1194-infected C3
2/2 mice, although
these differences were not significant until 8 dpi when the viral
titers in WT mice were 10
3.5 TCID50/ml as compared to 10
5.75
TCID50/ml (p,0.02) in C3
2/2 infected mice. Overall, these
studies suggest that C3 is an important host response during
influenza infection; potentially by aiding in viral clearance and
regulating lung inflammation.
Discussion
Here, we present data that the complement component C3 is
required for protection from pandemic 2009 H1N1 and HPAI
H5N1 influenza virus infections by aiding in viral clearance and
regulating lung inflammation. Our work complements previous
studies demonstrating a protective role for C3 against mouse-
adapted strains of influenza virus [25,26,27]. These studies
demonstrated that complement C3 was important for T-cell
C3 Protects during Influenza Infection
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17377Figure 1. Complement levels in BAL during influenza infection. On days 1, 3, and 6 post-infection, BAL was collected from mice inoculated
with PBS (control) or infected with PR/8, CA/09, or VN/1194 influenza virus and analyzed for complement C3 (A) or C5a levels (B) by sandwich ELISA.
Error bars represent standard deviation. (C) C3 processing in the BAL of uninfected and influenza-infected mice at different times post-infection were
analyzed by western blot analysis and results quantitated by densitometry (D). Results are representative of 2 separate experiments.
doi:10.1371/journal.pone.0017377.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17377priming and migration to the lung [27] and promoting the
expansion of CD8+ and CD4+ T cells during infection [28]. The
lack of T cell priming, expansion and migration in the C3
2/2
mice could explain the delayed viral clearance.
The complement system is a major component of innate
immunity and consists of both soluble factors and cell surface
receptors that interact to sense and respond to invading pathogens.
Three general activation pathways, referred to as the classical,
Figure 2. Increased inflammation and innate immune cells of influenza infected C3
2/2 mice at 3 dpi. At 3 days post-infection, lung
tissue was collected, formalin-fixed, and paraffin-embedded. Sections (4 mm thick) were stained with hematoxylin and eosin (A, B, G, H, M, N) or for
macrophages (C, D, I, J, O, P), or neutrophils (E, F, K, L, Q, R). Representative pictures of each group are shown at 206magnification.
doi:10.1371/journal.pone.0017377.g002
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alpha and beta chain), the central component of the complement
system. Formation of C3 convertases leads to cleavage of C3 to its
active fragments, the anaphylatoxin C3a and the opsonin C3b.
This cleavage event exposes a reactive thioester that allows
covalent attachment of C3b to target surfaces. C3b can be further
cleaved into the signaling fragments iC3b, C3dg, and C3d which
regulate phagocytosis and a variety of other immune cell effector
functions. In addition, C3b binds the C3 convertases resulting in a
substrate change from C3 to C5, which is cleaved to the
anaphylatoxin C5a and the initiator of the membrane attack
complex C5b.
Figure 3. Increased inflammation and innate immune cells of influenza infected C3
2/2 mice at 6 dpi. At 6 days post-infection, lung
tissue was collected, formalin-fixed, and paraffin-embedded. Sections (4 mm thick) were stained with hematoxylin and eosin (A, B, G, H, M, N) or for
macrophages (C, D, I, J, O, P), or neutrophils (E, F, K, L, Q, R). Representative pictures of each group are shown at 206magnification.
doi:10.1371/journal.pone.0017377.g003
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required for host defense, the levels of C3 and complement
activation fragments in BAL differed amongst the different
influenza virus infections. We failed to detect any significant
increase in total C3 levels in the BAL of PR/8 or 2009 pandemic
CA/09 virus infected mice as compared to uninfected controls
using a mouse-specific C3 sandwich ELISA. In contrast, increased
levels of total C3 were detected in the BAL of mice inoculated with
H5N1 VN/1194. Increased levels of C5a, a marker of comple-
ment activation and a potent anaphylatoxin, were also detected in
the BAL of H5N1 VN/1194 inoculated mice, but not mice
inoculated with either PR/8 or CA/09. To further investigate
activation of the complement system by the different influenza
virus infections, immunoblot analyses of BAL were performed.
Consistent with the C3 and C5a ELISA data, increased levels of
the C3 beta chain, which is not proteolytically processed and
serves as a marker for total C3 levels, and iC3b, which is derived
from the proteolysis of the C3 alpha chain and serves as a marker
of complement activation, were detected in BAL collected from
mice inoculated with H5N1 VN/1194. In addition, immunoblot
analyses detected an increase in iC3b levels at 3 dpi in BAL
collected from CA/09 virus infected mice. Taken together, these
results suggest that CA/09 and H5N1 VN/1194 are more
powerful activators of the complement system compared to PR/
8 infection. The reasons for the differences amongst the viruses
and the viral genes involved are under investigation.
Increased complement activation can be associated with
enhanced viral pathogenesis. For example, compared to WT
animals, complement-depleted mice infected with Sindbis virus
had less morbidity and mortality despite increased viral replication
and spread, suggesting a potentially pathologic role for comple-
ment [29,30]. Similar results occurred with the arthritogenic
alphavirus Ross River Fever virus in which complement-deficient
mice exhibited far less severe disease signs and tissue damage than
WT mice despite similar viral titers [24,31,32]. Because of this, we
hypothesized that the increased complement levels in the HPAI
H5N1 infected mice could be associated with the enhanced
inflammation associated with these infections. Pathological
examination demonstrated that the H5N1 VN/1194 infected
WT mice had enhanced inflammation as compared to the
pandemic 2009 H1N1 CA/09 infection within 3 dpi. However,
the inflammation was exacerbated in the infected C3
2/2 animals
Figure 4. Increased morbidity in influenza infected C3
2/2 mice. (A) Digital images of the slides was obtained and the percentage of positive
nuclei in four random sections of the lung for each animal were determined with ImageScope using a nuclear-based algorithm. (B) C57BL/6 (WT) or
C3
2/2 mice were inoculated i.n. with equivalent MID50 units of CA/09 (10
5 TCID50, n=14) or VN/1194 (10
4 TCID50, n=14) influenza virus and weights
monitored every 48 hpi (A). Error bars represent standard error deviation.
doi:10.1371/journal.pone.0017377.g004
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17377suggesting that C3 plays a protective role during influenza
infection.
In summary, the results of our studies suggest that complement
contributes to protection against 2009 pandemic H1N1 and HPAI
H5N1 influenza infection in mice. Given that complement
polymorphisms are common and can be associated with increased
susceptibility to several infectious diseases [33,34,35,36], it would
be interesting to determine the state of complement activation
during influenza infection in humans and assess the role in disease
severity.
Materials and Methods
Ethics statement
All procedures involving animals were approved by the
University of Wisconsin-Madison School of Medicine and Public
Health, and the St. Jude Children’s Research Hospital IACUC’s
and was in compliance with the Guide for the Care and Use of
Laboratory Animals. These guidelines were established by the
Institute of Laboratory Animal Resources and approved by the
Governing Board of the U.S. National Research Council.
Laboratory facilities
All experiments using H5N1 viruses were conducted in a
Biosafety level 3 enhanced containment laboratory [37]. Investi-
gators were required to wear appropriate respirator equipment
(RACAL, Health and Safety Inc., Frederick, MD). Mice were
housed in HEPA-filtered, negative pressure, vented isolation
containers.
Viruses and cells
A/Puerto Rico/8/34 (PR/8) and A/California/04/2009 (CA/
09, provided by Dr. Jacco Boon, St. Jude Children’s Research
Hospital) H1N1 viruses were propagated in the allantoic cavity of
10-day-old specific pathogen-free embryonated chicken eggs at
37uC. Allantoic fluid was harvested, clarified by centrifugation and
stored at 270uC. A/Vietnam/1194/2004 (VN/1194) (provided
by Dr. Alexander Klimov; CDC, Atlanta, Georgia) was propa-
gated in Madin Darby canine kidney (MDCK) cells as described
[38]. MDCK cells were cultured in Eagle’s minimum essential
medium supplemented with 4.5 g glucose per liter, 2 mM
glutamine (Mediatech), and 10% FBS (Gemini BioProducts, West
Sacramento, CA) and grown at 37uC under 5% CO2.
Viral titers
Viral titers were determined by tissue culture infectious dose 50
(TCID50) assays on MDCK cells as described [38] and quantitated
by Reed and Muench analysis [39]. Results are expressed as the
mean log10 TCID50/ml.
Animal experiments
10–12 week of age female C57BL/6J (WT) or C3
2/2
(B6.129S4-C3
tm1Crr/J) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). For infection, mice were lightly
anesthetized using isofluorane and intranasally (in) inoculated with
PBS or equivalent mouse infectious dose 50 (MID50) of PR/8
(1610
4 TCID50), CA/09 (1610
5 TCID50), or VN/1194 (1610
4
TCID50)i n2 5ml PBS. Mice were monitored daily for clinical
signs of infection [40] and weighed every 48 hpi. At different times
post-infection, two control and three infected mice were
anesthetized, terminally bled, and lungs harvested. The large lung
lobe was washed and immediately stored in 10% buffered formalin
for histological analysis. The remaining lobe was homogenized in
1 ml PBS and viral titers determined by TCID50 analysis.
Histopathology and immunohistochemical staining
Tissues were fixed in 10% neutral buffered formalin solution,
processed, and paraffin embedded. Four micron thick sections
were stained with hematoxylin and eosin or for macrophages
(Mac2/Galectin 2, 1:1000, Abcam, Cambridge, MA) or neutro-
phils (NeuN, 1:1000, Abcam) by the St. Jude Veterinary Pathology
Core Facility. Digital images were obtained with ScanScope
(Aperio, Vista, CA) and the percentage of positive nuclei in four
random sections of the lung for each animal were determined with
ImageScope (www.apeiro.com) using a nuclear-based algorithm.
Complement component C3 and C5a ELISA
Protein levels were determined in BAL by BCA Protein Assay
(Pierce, Rockford, IL) and C3 and C5a levels were quantitated by
sandwich ELISAs (GenWay Biotech Inc, San Diego, CA and
R&D Systems, Minneapolis, MN respectively) using equivalent
protein concentrations following manufacturer’s instructions.
Western blot
Equivalent volumes (30 ml) of BAL were separated by SDS-
PAGE under reducing conditions and transferred to a nitrocellu-
lose membrane using the iBlot Dry Blotting system (Invitrogen,
Carlsbad, CA). The membrane was blocked with 5% dry milk in
TBS containing 0.1% Tween-20 (TTBS), and probed with goat
anti-mouse C3 antibody (1:1000; Cappel) or goat anti-actin
antibody (1:1000 Santa Cruz) overnight at 4uC. After extensive
washes, membranes were incubated with a donkey anti-goat HRP-
conjugated antibody (1:10,000; Southern Biotechnology, Birming-
ham, AL) for 1 h at room temperature, and signal was detected
using the SuperSignal West Pico Chemiluminescent Substrate
(Pierce). Densitometry was performed on scanned immunoblot
images using the ImageJ gel analysis tool. The gel analysis tool was
used to obtain the absolute intensity (AI) for each experimental
complement band and corresponding actin control band. The
ratios for each experimental band was calculated by dividing the
corresponding control AI by the experimental AI to determine the
fold change as compared to the uninfected control samples.
Figure 5. Delayed viral clearance in influenza infected C3
2/2
mice. C57BL/6 (WT) or C3
2/2 mice were inoculated i.n. with equivalent
MID50 units of CA/09 (10
5 TCID50, n=14) or VN/1194 (10
4 TCID50, n=14)
influenza virus. At 3, 6, and 8 days post-infection, lung homogenates
were monitored for viral titers by TCID50 analysis on MDCK cells. Error
bars represent standard deviation and asterisk (*) indicates significant
increase in viral titers as compared with WT infected mice.
doi:10.1371/journal.pone.0017377.g005
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17377Statistical analyses
Statistical significance of data was determined by using analysis
of variance (ANOVA) or Student’s t- test on GraphPad Prism (San
Diego, CA). All assays were run in triplicate and are representative
of at least 2 separate experiments. Error bars represent standard
deviation and statistical significance was defined as a p value of less
than 0.05.
Supporting Information
Figure S1 Complement activation products in BAL
during influenza infection. On days 1, 3, and 6 post-infection,
BAL was collected from mice inoculated with PBS (control) or
infected with PR/8, CA/09, or VN/1194 influenza virus and
analyzed for complement C3 activation products by western blot
analysis. Results are representative of 2 separate experiments.
(TIF)
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